Sinovac Biotech Ltd (SVA) stock
SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.47+0.00 (0.00%)
Close on Nov 17, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$490.13M. The highest annual figure on record is $17.62B in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$490.13M | – |
| FY2024 | Dec 31, 2024 | -$505.54M | – |
| FY2023 | Dec 31, 2023 | -$713.98M | – |
| FY2022 | Dec 31, 2022 | -$508.99M | -102.9% |
| FY2021 | Dec 31, 2021 | $17.62B | +8070.1% |
| FY2020 | Dec 31, 2020 | $215.64M | +214.5% |
| FY2019 | Dec 31, 2019 | $68.56M | +51.3% |
| FY2018 | Dec 31, 2018 | $45.32M | -0.2% |
| FY2017 | Dec 31, 2017 | $45.42M | +8911.3% |
| FY2016 | Dec 31, 2016 | $504.00K | -86.4% |
| FY2015 | Dec 31, 2015 | $3.70M | +96.0% |
| FY2014 | Dec 31, 2014 | $1.89M | -81.0% |
| FY2013 | Dec 31, 2013 | $9.95M | – |
| FY2012 | Dec 31, 2012 | -$21.15M | -726.9% |
| FY2011 | Dec 31, 2011 | $3.37M | – |
| FY2010 | Dec 31, 2010 | -$13.36M | -131.7% |
| FY2009 | Dec 31, 2009 | $42.15M | – |
See a number that looks wrong?